Frontiers

Bench to Bedside Winter 2013 

Tags:
Phase II study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features

HYPOTHESIS:

Low-dose lenalidomide will enhance the efficacy of vaccination for infectious diseases among patients with CLL as measured by antibody response to pneumonia vaccination with conjugated 13-valent pneumococcal vaccine. Low-dose lenalidomide can also induce complete remissions in asymptomatic patients with high genomic risk CLL, delaying the time to first conventional therapy.

STUDY DESIGN:

Patients are randomized to one of two treatment arms. Oral low-dose lenalidomide is administered daily on a continuous basis for at least 24 28-day courses in the absence of disease progression or unacceptable toxicity. Patients also receive two doses of 13-valent protein-conjugated pneumococcal vaccine (PCV13) intramuscularly concurrent with or sequential to lenalidomide, depending upon treatment arm.

RATIONALE:

OSU-10156 investigates the use of lenalidomide and vaccine therapy for treating early-stage, asymptomatic CLL or SLL. Survival of CLL patients ranges from months to more than 20 years, but infectious complications account for 30-50 percent of deaths. Unfortunately, many of the most common therapies for CLL (e.g., fludarabine, alkylating agents) can increase the risk for infection.

Standard care for CLL involves treating only symptomatic disease. Routine treatment of early-stage CLL is generally not considered beneficial. However, a subgroup of patients is at high-risk for early progression and death. For example, patients with CLL cells showing unmutated immunoglobulin heavy-chain genes (IgVH), a complex karyotype and deletions of chromosomes 11q22.3 and 17p13.1 demonstrate a shorter treatment-free interval and impaired survival.

Lenalidomide is a potent immunomodulatory analogue of thalidomide. Its immunomodulatory effects include stimulating T-cell proliferation and production of IL-2, IL-10 and IFN- γ. The agent has shown promising activity in both untreated and relapsed/refractory CLL, including patients with high-risk genomic features.

Evidence suggests that lenalidomide can promote both cellular and innate immune activation, and the drug has effected both remissions and improvement of immune-system parameters when given to patients with symptomatic CLL/SLL. Lenalidomide might further benefit patients if administered earlier in the disease course, when humoral and cellular immune mechanisms are more intact.

The Prevnar 13 (PCV13) vaccine is a conjugate vaccine for prevention of disease caused by the 13 pneumococcal serotypes. Research has shown that such vaccines are not only safe but also potentially more effective in several immunocompromised adult populations. Additionally, preliminary findings from a study of protein-conjugated pneumococcal vaccine and lenalidomide in multiple myeloma patients suggest that the vaccine and lenalidomide interact to boost immune responses.

OSU-10156 will help determine whether early treatment of earlystage, high-risk CLL patients with the PCV13 vaccine and either concurrent or sequential lenalidomide will help prevent immune deterioration in early-stage disease. Key objectives include determining the complete response rate after two years of lenalidomide therapy and determining the incidence of infection, particularly invasive pneumococcal infections.

AT A GLANCE
Trial no.: OSU-10156 (ClinicalTrial.gov identifier NCT01351896

PI: JEFFREY A. JONES, MD, MPH

Phone: 614-293-3507

Email: jeffrey.jones@osumc.edu

Eligibility: Histologically confirmed, asymptomatic CLL/SLL with at least one high-risk genomic feature; age ≥ 18 years; ECOG performance status ≤ 2; non-pregnant and/or using adequate birth control; no previous treatment for CLL/SLL; no history of AIHA/ITP; no VTE events within 6 months; estimated life expectancy ≥ 24 months
 
13-Feb-13
19  Comments  |  Trackback Url  | 0  Link to this post

Bookmark this post with:        
 

Links to this post

Comments


Hudyonesullivan  commented on  Monday, November 11, 2013  1:00 PM 
Marie-Chantal,I stumbled upon your blog while loiknog up symptoms of GVHD and I am so glad I did. I am a survivor of CML, well I guess I'm not in remission anymore but I still like to say I'm a survivor I am not really a blog type of person but I just couldn't leave your page once I found it. You are so amazing! I haven't read very much but what I have read is just wow. I really enjoy your writing style, it's really personal and I love your sense of humor. We got to keep our sense of humor to survive!I was diagnosed in 2006 when I was 17 and had my transplant the following year. I was in remission until a few years ago and have been taking Sprycel to keep things under wraps ever since. I just had a Donor Lymphocyte Infusion in Feb. and I think that's what triggered my second GVHD experience. I'm at the early stages right now but those tiny little bumps are spreading pretty quick. It always amazes me how quickly one's body can betray itself. I have been revisiting the time I spent in the hospital and the dear friend I met and lost on the cancer unit we were treated on. Your blog is inspiring and you are a beautiful person. I have been thinking of writing a book about my journey, maybe I can get some pointers from you?


with free insurance car  commented on  Wednesday, December 25, 2013  3:45 AM 
Well I guess I don't have to spend the weekend figuring this one out!


cheap prednisone  commented on  Wednesday, January 01, 2014  12:04 AM 
Thanks for sharing. Your post is a useful contribution.


online slots all usa  commented on  Thursday, January 02, 2014  11:43 AM 
Wow, this is in every respect what I needed to know.


www.coverageservices.net  commented on  Saturday, January 04, 2014  6:30 PM 
I'm not easily impressed. . . but that's impressing me! :)


share  commented on  Wednesday, January 08, 2014  6:05 AM 
Just what the doctor ordered, thankity you!


car insurance driving instructor  commented on  Thursday, January 09, 2014  2:26 PM 
It's much easier to understand when you put it that way!


slots  commented on  Tuesday, January 14, 2014  10:02 PM 
Great common sense here. Wish I'd thought of that.


generic cialis  commented on  Sunday, January 19, 2014  3:36 AM 
That's way the bestest answer so far!


car insurance quotes  commented on  Tuesday, January 21, 2014  1:38 PM 
That's a smart way of thinking about it.


how to play blackjack  commented on  Saturday, January 25, 2014  11:14 AM 
You've captured this perfectly. Thanks for taking the time!


momniscient.net  commented on  Thursday, January 30, 2014  1:32 AM 
I'm grateful you made the post. It's cleared the air for me.


car insurance 1 month  commented on  Sunday, February 02, 2014  1:09 PM 
It was dark when I woke. This is a ray of sunshine.


businesstheory.org  commented on  Wednesday, August 27, 2014  12:15 AM 
This is a common attitude because change is a good thing for business, and organizations implement changes all of the time to make improvements on processes, productivity, and efficiency. Here are a few ways you can make the transition of change easier for your employees.


capitalbusinessnetwork  commented on  Wednesday, August 27, 2014  12:16 AM 
it helps to reach wider audiences and perhaps maximize client base in the process. A very famous entrepreneur Robert Kiyosaki once stated that the rich get where they are because they understand the value of creating strong networks


counselingeducation  commented on  Wednesday, August 27, 2014  12:16 AM 
In choosing the right counselor you will need to think about what you want and what is required by your insurance company (if you are using one) so that you get the highest education and most information.


ormistoneducation  commented on  Wednesday, August 27, 2014  12:16 AM 
Dedication is required of any journalist, but it takes a special kind of reporter to film and photograph war zones as they rage uncontrollably. I'm not speaking heroically; my intuition tells me these men and women are driven


creativeeducationsummit  commented on  Wednesday, August 27, 2014  12:17 AM 
Summit has easy access to the Midtown Direct for those of you who commute into New York for work or play and want a good investment at the same time.


usamm  commented on  Wednesday, October 08, 2014  7:28 AM 
Wonderful work done by your site in providing awe some job opportunities to us. Au pair is my favorite choice when it comes to find appropriate jobs..

Name *:
URL:
Email:
Comments:

CAPTCHA Image Validation